RXRX — Recursion Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.21bn
- $1.64bn
- $58.84m
- 38
- 12
- 49
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.14 | ||
| Price to Tang. Book | 4.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 37.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.98% | ||
| Return on Equity | -61.89% | ||
| Operating Margin | -814.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.96 | 10.18 | 39.84 | 44.58 | 58.84 | 90.74 | 137.49 | 90.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.
Directors
- R. Martin Chavez NEC (57)
- Tina Larson PRE (46)
- Christopher Gibson CEO (38)
- Michael Secora CFO (38)
- Heather Kirkby CHO (49)
- Benjamin Mabey CTO (38)
- Sharathchandra Hegde CSO (57)
- Louisa Daniels GCN (63)
- Ramona Doyle OTH
- Mason Victors OTH (34)
- Shafique Virani OTH (50)
- Zachary Bogue IND
- Blake Borgeson IND (39)
- Terry - Ann Burrell IND (44)
- Zavain Dar IND (32)
- Robert Hershberg IND (57)
- Dean Li IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 4th, 2013
- Public Since
- April 16th, 2021
- No. of Shareholders
- 149
- No. of Employees
- 840
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 401,990,669
- Address
- 41S Rio Grande Street, SALT LAKE CITY, 84101
- Web
- https://www.recursion.com/
- Phone
- +1 3852690203
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for RXRX
Recursion Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Recursion Pharmaceuticals Inc Earnings Release
Similar to RXRX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Recursion Pharmaceuticals share price?
As of Today at 22:51 UTC, shares in Recursion Pharmaceuticals are trading at $5.50. This share price information is delayed by 15 minutes.
How has the Recursion Pharmaceuticals share price performed this year?
Shares in Recursion Pharmaceuticals last closed at $5.50 and the price had moved by -26.37% over the past 365 days. In terms of relative price strength the Recursion Pharmaceuticals share price has underperformed the S&P500 Index by -30.77% over the past year.
What are the analyst and broker recommendations for Recursion Pharmaceuticals?
The overall consensus recommendation for Recursion Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Recursion Pharmaceuticals dividend yield?
Recursion Pharmaceuticals does not currently pay a dividend.
Does Recursion Pharmaceuticals pay a dividend?
Recursion Pharmaceuticals does not currently pay a dividend.
When does Recursion Pharmaceuticals next pay dividends?
Recursion Pharmaceuticals does not currently pay a dividend.
How do I buy Recursion Pharmaceuticals shares?
To buy shares in Recursion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Recursion Pharmaceuticals?
As of the previous close price of $5.50, shares in Recursion Pharmaceuticals had a market capitalisation of $2.21bn.
Where are Recursion Pharmaceuticals shares listed?
Here are the trading details for Recursion Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RXRX
What kind of share is Recursion Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Recursion Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Recursion Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Recursion Pharmaceuticals is $8.50. That is 54.55% above the last closing price of $5.50.
Analysts covering Recursion Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.63 for the next financial year.
Find out moreWhat is the trend in the Recursion Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Recursion Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -12.18%.
As of the last closing price of $5.50, shares in Recursion Pharmaceuticals were trading -20.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Recursion Pharmaceuticals PE Ratio?
The Recursion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Recursion Pharmaceuticals?
Recursion Pharmaceuticals' management team is headed by:
- R. Martin Chavez - NEC
- Tina Larson - PRE
- Christopher Gibson - CEO
- Michael Secora - CFO
- Heather Kirkby - CHO
- Benjamin Mabey - CTO
- Sharathchandra Hegde - CSO
- Louisa Daniels - GCN
- Ramona Doyle - OTH
- Mason Victors - OTH
- Shafique Virani - OTH
- Zachary Bogue - IND
- Blake Borgeson - IND
- Terry - Ann Burrell - IND
- Zavain Dar - IND
- Robert Hershberg - IND
- Dean Li - IND